New Drug Applications

Complete Response Letter Issued for Remoxy

Written by David Miller

AUSTIN, Texas, Aug. 06, 2018 (GLOBE NEWSWIRE) — Pain Therapeutics, Inc. (Nasdaq: PTIE) today announced it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Remoxy,…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]